Assay Development for Screening of Specific IKKalpha Kinase Inhibitors
Assay Development for Screening of Specific IKKalpha Kinase Inhibitors
批准号:
8182644
负责人:
Jun-Li Luo
金额:
$19.8万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-07-01 至 2013-06-30
关键词:
AblationAdverse effectsAnimal ModelAnimalsB-LymphocytesBiological AssayBreast Cancer CellBreast Cancer TreatmentCancer cell lineCell LineCell NucleusCell ProliferationCell SurvivalCellsChemicalsComplexCytoplasmDefectDevelopmentDimethyl SulfoxideFloridaGeneticGenetic TranscriptionGoalsHumanImmune responseInflammationLuciferasesMAP3K1 geneMAP3K7 geneMAPK14 geneMCF7 cellMalignant neoplasm of prostateMeasuresMethodsMusNF-kappa BNeoplasm MetastasisNuclearPC3 cell linePathway interactionsPeptidesPhosphorylationPhosphotransferasesPhysiologicalPlasmidsPlayProto-Oncogene Proteins c-aktReporterReproducibilityResearchResistanceRoleScreening procedureSeriesSignal TransductionSystemTBK1 geneTimeValidationVariantassay developmentbasecancer therapycell motilitydensityfollow-uphigh throughput screeninginhibitor/antagonistkinase inhibitormalignant breast neoplasmmaspinpromoterresearch studyresponsetherapy developmenttranscription factor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Although IKK1 and IKK2 are highly homologous, their functions are very unique. Specifically, IKK2 locates in the cytoplasm and functions through NF-kB pathways whereas IKK1 can translocate to and function in the nucleus that is independent of classical and alterative NF-kB pathways. Recent studies have demonstrated that IKK1 kinase plays a pivotal role in breast and prostate cancer development and cancer therapy resistance, suggesting that IKK1 kinase is an excellent target for cancer therapy. However, currently there are no IKK1 kinase-specific inhibitors or the methods for the discovery of IKK1 kinase-specific inhibitors available. In the proposed project we plan to develop a functional cell-based high-throughput screening (HTS) assay to identify specific inhibitors for IKK1 kinase. This assay utilizes the newly discovered function of nuclear IKK1 kinase that suppresses maspin transcription. We transfected human breast cancer cell line MCF7 with plasmid containing maspin promoter-driven luciferase reporter and established two stable reporter cell lines. These cell lines will be further characterized for HTS development. The density, incubation time, dimethyl sulfoxide (DMSO) concentration used to screen the IKK1 kinase specific inhibitors will also be optimized. In addition, we will establish a complementary assay and a series of counter-screen assays for the validation and prioritization of IKK1 kinase inhibitor candidates. Our studies will establish a high-selective and high-efficient functional cell- based HTS assay for the discovery of IKK1 kinase specific inhibitors. We will submit this assay to MLPCN when the project is completed. In our follow-up studies, promising candidates from screens will be examined further for their ability to inhibit IKK1 kinase activity, maspin expression, cell proliferation and/or motility in human breast and prostate cancer cell lines, and their ability to suppress breast and prostate cancer development, progression, metastasis, and therapy-resistance in animal models.
PUBLIC HEALTH RELEVANCE: IKK1 kinase plays a pivotal role in breast and prostate cancer development and therapy-resistance, suggesting that IKK1 kinase is an excellent target for breast and prostate cancer treatment. However, currently there are no IKK1 kinase-specific inhibitors or the methods for the discovery of IKK1 kinase-specific inhibitors available. Our studies will establish a high-selective and high-efficient functional cell-based high-throughput screen system for the discovery of IKK1 kinase-specific inhibitors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of cancer therapeutic TBK1/IKKi dual inhibitors
-
批准号:9893827
-
项目类别:
-
资助金额:$43.92万
-
财政年份:2016
-
负责人:Jun-Li Luo
-
依托单位:
Development of cancer therapeutic TBK1/IKKi dual inhibitors
-
批准号:9248311
-
项目类别:
-
资助金额:$43.92万
-
财政年份:2016
-
负责人:Jun-Li Luo
-
依托单位:
Immune-inflammatory signaling and hormone-refractory prostate cancer evolution.
-
批准号:8637936
-
项目类别:
-
资助金额:$39.35万
-
财政年份:2011
-
负责人:Jun-Li Luo
-
依托单位:
Immune-inflammatory signaling and hormone-refractory prostate cancer evolution.
-
批准号:8235834
-
项目类别:
-
资助金额:$40.57万
-
财政年份:2011
-
负责人:Jun-Li Luo
-
依托单位:
Immune-inflammatory signaling and hormone-refractory prostate cancer evolution.
-
批准号:8042328
-
项目类别:
-
资助金额:$43.02万
-
财政年份:2011
-
负责人:Jun-Li Luo
-
依托单位:
Immune-inflammatory signaling and hormone-refractory prostate cancer evolution.
-
批准号:8449737
-
项目类别:
-
资助金额:$38.13万
-
财政年份:2011
-
负责人:Jun-Li Luo
-
依托单位:
海外基金